Umezawa K, Ariga A, Matsumoto N
Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Japan.
Anticancer Drug Des. 2000 Aug;15(4):239-44.
Nuclear factor (NF)-kappaB is a transcription factor that induces the immunoglobulin kappa chain, cytokines such as interleukin (IL)-1, IL-2, IL-6, IL-8, tumor necrosis factor (TNF)-alpha and interferon gamma, and cell adhesion proteins. It also induces anti-apoptotic proteins, and inhibits TNF-alpha and anticancer drug-induced apoptosis. Therefore, NF-kappaB function inhibitors may be useful as anti-inflammatory and anticancer agents. Microbial products such as panepoxydone, cycloepoxydon and gliotoxin are known to inhibit activation of NF-kappaB. We have designed and synthesized new NF-kappaB inhibitors from the structure of an antibiotic, epoxyquinomicin C. The designed compound, DHM2EQ, inhibited TNF-alpha-induced activation of NF-kappaB and showed a therapeutic effect in mouse rheumatoid arthritis model.
核因子(NF)-κB是一种转录因子,可诱导免疫球蛋白κ链、细胞因子如白细胞介素(IL)-1、IL-2、IL-6、IL-8、肿瘤坏死因子(TNF)-α和干扰素γ以及细胞粘附蛋白。它还能诱导抗凋亡蛋白,并抑制TNF-α和抗癌药物诱导的细胞凋亡。因此,NF-κB功能抑制剂可能作为抗炎和抗癌药物发挥作用。已知微生物产物如泛环氧薁、环环氧薁和gliotoxin可抑制NF-κB的激活。我们从抗生素环氧喹霉素C的结构设计并合成了新的NF-κB抑制剂。设计的化合物DHM2EQ可抑制TNF-α诱导的NF-κB激活,并在小鼠类风湿性关节炎模型中显示出治疗效果。